GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (FRA:04K) » Definitions » E10

Knight Therapeutics (FRA:04K) E10 : €0.28 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Knight Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was €-0.027. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.28 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-09), Knight Therapeutics's current stock price is €3.88. Knight Therapeutics's E10 for the quarter that ended in Mar. 2024 was €0.28. Knight Therapeutics's Shiller PE Ratio of today is 13.86.

During the past 11 years, the highest Shiller PE Ratio of Knight Therapeutics was 15.28. The lowest was 13.18. And the median was 14.15.


Knight Therapeutics E10 Historical Data

The historical data trend for Knight Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics E10 Chart

Knight Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.27

Knight Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.27 0.28

Competitive Comparison of Knight Therapeutics's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Shiller PE Ratio falls into.



Knight Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Knight Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.027/126.2576*126.2576
=-0.027

Current CPI (Mar. 2024) = 126.2576.

Knight Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 0.004 99.473 0.005
201409 0.005 99.394 0.006
201412 1.535 98.367 1.970
201503 0.110 99.789 0.139
201506 0.065 100.500 0.082
201509 0.047 100.421 0.059
201512 0.033 99.947 0.042
201603 0.003 101.054 0.004
201606 0.027 102.002 0.033
201609 0.027 101.765 0.033
201612 0.043 101.449 0.054
201703 0.028 102.634 0.034
201706 0.002 103.029 0.002
201709 0.017 103.345 0.021
201712 0.032 103.345 0.039
201803 0.031 105.004 0.037
201806 0.018 105.557 0.022
201809 0.059 105.636 0.071
201812 0.002 105.399 0.002
201903 0.026 106.979 0.031
201906 0.088 107.690 0.103
201909 -0.014 107.611 -0.016
201912 -0.034 107.769 -0.040
202003 -0.006 107.927 -0.007
202006 0.087 108.401 0.101
202009 0.090 108.164 0.105
202012 0.039 108.559 0.045
202103 0.020 110.298 0.023
202106 0.156 111.720 0.176
202109 -0.047 112.905 -0.053
202112 -0.041 113.774 -0.045
202203 -0.115 117.646 -0.123
202206 0.015 120.806 0.016
202209 0.008 120.648 0.008
202212 -0.090 120.964 -0.094
202303 -0.027 122.702 -0.028
202306 0.014 124.203 0.014
202309 0.062 125.230 0.063
202312 -0.157 125.072 -0.158
202403 -0.027 126.258 -0.027

Add all the adjusted EPS together and divide 10 will get our e10.


Knight Therapeutics  (FRA:04K) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Knight Therapeutics's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=3.88/0.28
=13.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Shiller P/E Ratio of Knight Therapeutics was 15.28. The lowest was 13.18. And the median was 14.15.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Knight Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Knight Therapeutics (FRA:04K) Business Description

Traded in Other Exchanges
Address
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Knight Therapeutics (FRA:04K) Headlines

No Headlines